Novo Nordisk To Target 'New GLP-1 Patients Only' With Weekly Ozempic

 
• By Sten Stovall

Novo Nordisk's head of international operations says trying to switch diabetes patients over to newly approved Ozempic from other GLP-1 medicines is not part of its commercial strategy.

Diabetes
Ozempic Is Newest Once-Weekly GLP-1 Agonist To Reach Market For Type 2 Diabetes • Source: Shutterstock

More from Strategy

More from Business